Reach Us +1-217-403-9671
What Is The Place Of Knemometry In Development Of New Inhaled Corticosteroids | 8289
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

What is the place of knemometry in development of new inhaled Corticosteroids

International Conference and Exhibiton on Pharmaceutical Regulatory Affairs

Ole D. Wolthers

ScientificTracks Abstracts: JBB

DOI: 10.4172/0975-0851.1000107

D evelopment of new inhaled corticosteroid s with an improved ratio between effi cacy and systemic activity for treatment of asthma is n eeded. Especially, growth suppression is an unwanted adverse eff ect in children. When validated recommendations for standardisation and measurement procedures are used short term assessment of lower leg growth by knemometry is a highly accurate and reproducible method for assessment of systemic activity of inhaled corticosteroids in children. In populations of children short term knemometry is to be capable of defi ning specifi c corticosteroids, application devices and doses that do not suppress long term height growth. If the short term lower leg growth suppression in populations of children is higher than approximately 25% the risk of intermediate term growth suppression becomes signifi cant with a mean height growth rate retardation in the range of approximately 1 cm during the fi rst year of treatment which may be associated with a reduction in fi nal height of the same magnitude. Short term knemometry should be performed as an integral part of the safety assessments of new inhaled corticosteroids an d inhalation devices in children with asthma before intermediate term or long term height growth evaluations are initiated